C2iT
C2IT Platform
The Exploratory Clinical Trials Center in Immunotherapy (C2IT) of the Marseille Immunology Biocluster (MIB) provides multidisciplinary and cross-functional expertise in immunotherapy.
C2IT brings together the strengths of AP-HM and IPC for early-phase clinical studies and addresses
- Oncology
Two leading centers for early-phase clinical trials (CLIPP):- Accredited by the French National Cancer Institute (INCa)
- Authorized to conduct Phase I clinical trials, including First-in-Human (FIH) studies
- Two adult centers and one pediatric center
- Autoimmunity / Inflammation
One Clinical Investigation Center (CIC) authorised to conduct Phase I clinical trials, including First-in-Human (FIH) studies. - Infectious Diseases
- Central Laboratory Accredited by COFRAC under ISO 15189 and ISO 22870 standards
- Additional infrastructures
- Immunotoxicity network for the management of adverse events
- A wide panel of preclinical and translational platforms, including immunomonitoring
- Health Data Warehouses (EDS)
Légende de l’image à remplacer
One of the biocluster’s mission is to provide patients with access to innovative treatments in oncology ; autoimmune, inflammatory, and infectious diseases. MIB C2IT gives to patients access to up to 110 clinical trials per year (including about 60 Phase I/II trials) aiming at evaluating new therapies.
To maximize benefits for patients, C2IT simultaneously conducts translational studies and predictive biomarker research supporting precision medicine in immunology.
Furthermore, the development of innovative projects requires access to clinical trials, biological samples and associated data,facilitated by C2IT.
Integrated within the MIB ecosystem, C2IT plays a central role within the technological hub, addressing challenges related to Advanced Therapy Medicinal Products (ATMPs), including cell therapies.
C2IT Expertise
C2IT service relies on multidisciplinary and cross-functional expertise covering a wide range of pathologies in oncology, autoimmunity, inflammation, and infectious diseases, as well as clinical and translational research management.
By providing access to its full range of resources, C2IT ensures:
Patient Recruitment
• Multiple oncology specialties (solid tumors and hematology)
• Autoimmune, inflammatory, and infectious diseases
• Adult and pediatric populations
Early-Phase Clinical Trials
• Inpatient or outpatient management
• Access to innovative therapeutic agents
• Monitoring and management of adverse events
• Management of biological samples (tissue and liquid biopsies, biological fluids, pharmacokinetics)
Immunotherapy Management
• Access to all classes of immunotherapy agents (including cell therapies)
• Immunomonitoring
• Management of immunotoxicities
Translational and data Immunology Research
• Study of immune biomarkers
• Access to patient cohorts and biological collections
• Access to Health Data Warehouses (EDS) from partner institutions
Clinical Trial Sponsorship
• Design, conduct, and analysis of clinical studies
• Data management and biostatistics
• Monitoring and pharmacovigilance
These fully integrated services enable the efficient implementation of drug discovery and development programs.
C2iT
C2IT Governance and Organization
To ensure optimal handling of requests, C2IT is structured with:
- Steering Committee led by three medical professors representing two major areas of activity:
- Immuno-oncology (IO) : Prof. Pascale Tomasini – AP-HM and Prof. Anthony Gonçalves – IPC
- Autoimmune / Inflammatory / Infectious diseases (AI3D) : Prof. Noémie Jourde-Chiche – AP-HM
- This committee enables :
- Efficient feedback to study proposals requests (within 7 days)
- Efficient and large acces to patient cohorts between AP-HM and IPC sites, expanding recruitment capacity for clinical trials
- Scientific Working group defining the scientific and strategic decisions of C2IT research and development activities.
Its missions include:- Reviewing ongoing and upcoming studies, including academic research projects initiated by C2IT stakeholders
- Evaluating diagnostic and therapeutic clinical trials, as well as translational and data-driven research projects
- Reflecting on valorization and innovation strategies
- Organizing scientific activities and academic animation
- Administrative Working group bringing together resources from AP-HM and IPC across several departments:
- Research and Innovation
- Finance
- Human Resources
- Legal
Composition of the Scientific Working group
Oncology – IPC
- Anthony Gonçalves (IPC Lead – Medical Oncology)
- Yves Collette (IPC – TrGET Platform / CRCM)
- Alexandre De Nonneville (IPC – Medical Oncology)
- Sylvain Garciaz (IPC – Hematology)
- Emmanuel Mitry (IPC – Medical Oncology)
- Philippe Rochigneux (IPC – Medical Oncology)
- Cécile Vicier (IPC – Medical Oncology)
Oncology – AP-HM
- Pascale Tomasini (AP-HM Lead – Pulmonology / Oncology)
- Nicolas André (AP-HM – Pediatric Oncology)
- Julien Colle (AP-HM – Hematology)
- Caroline Gaudy (AP-HM – Onco-dermatology)
- Laurent Greillier (AP-HM – Pulmonology / Oncology)
- Arnaud Jeanson (AP-HM – Medical Oncology)
- Sébastien Salas (AP-HM – Medical Oncology)
- Emeline Tabouret (AP-HM – Neuro-oncology)
AI³D Pole
- Noémie Jourde-Chiche (AP-HM Lead – Nephrology)
- Florent Amatore (AP-HM – Dermatology)
- Shahram Attarian (AP-HM – Neurology)
- Nadim Cassir (AP-HM – Infectious Diseases)
- Pascal Chanez (AP-HM – Pulmonology / Allergology)
- Divi Cornec (Brest University Hospital – Rheumatology)
- Thomas Cuny (AP-HM – Endocrinology)
- Pierre-Edouard Fournier (AP-HM – Biology / Infectious Diseases)
- Lucas Guillo (AP-HM – Gastroenterology)
- Gilles Kaplanski (AP-HM – Internal Medicine)
- Jean-Christophe Lagier (AP-HM – Infectious Diseases)
- Anne Lepine (AP-HM – Pediatric Neurology)
- Matthieu Million (AP-HM – Infectious Diseases)
- Pierre Morange (AP-HM – Biology / Hematology)
- Jean Pelletier (AP-HM – Neurology)
- Thao Pham (AP-HM – Rheumatology)
- Nicolas Schleinitz (AP-HM – Internal Medicine)
Steering Committee
Prof. Anthony Gonçalves
Professor of Medicine and Hospital Practitioner, Aix-Marseille Université, IPC, Coordinator of the Department of Medical Oncology
Prof. Noémie Jourde Chiche
Professor of Medicine and Hospital Practitioner, Aix-Marseille Université, AP-HM, Head of the Clinical Nephrology Unit
Prof. Pascale Tomasini
Professor of Medicine and Hospital Practitioner, Aix-Marseille Université, AP-HM, Head of the Early-Phase Cancer Clinical Trials Center of Marseille – CLIP²